title: Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.
authors.affiliation: Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic and Mayo Clinic Cancer Center, Rochester, MN, USA.
authors.forename: Jin-Ping
authors.initials: JP
authors.lastname: Lai
authors.forename: Dalbir S
authors.initials: DS
authors.lastname: Sandhu
authors.forename: Chunrong
authors.initials: C
authors.lastname: Yu
authors.forename: Catherine D
authors.initials: CD
authors.lastname: Moser
authors.forename: Chunling
authors.initials: C
authors.lastname: Hu
authors.forename: Abdirashid M
authors.initials: AM
authors.lastname: Shire
authors.forename: Ileana
authors.initials: I
authors.lastname: Aderca
authors.forename: Linda M
authors.initials: LM
authors.lastname: Murphy
authors.forename: Alex A
authors.initials: AA
authors.lastname: Adjei
authors.forename: Schuyler
authors.initials: S
authors.lastname: Sanderson
authors.forename: Lewis R
authors.initials: LR
authors.lastname: Roberts
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D006528:Carcinoma, Hepatocellular / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D053148:Caspase 3 / Q000378:metabolism; D053179:Caspase 7 / Q000378:metabolism; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002867:Chromones / Q000494:pharmacology*; D019938:Cyclin D1 / Q000378:metabolism; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D048031:JNK Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008113:Liver Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D009025:Morpholines / Q000494:pharmacology*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D034622:RNA Interference; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction / Q000187:drug effects; D013429:Sulfatases; D015238:Sulfotransferases / Q000235:genetics / Q000378:metabolism*; D014162:Transfection; D051025:bcl-Associated Death Protein / Q000378:metabolism
chemical_list: D053148:Caspase 3; D053179:Caspase 7; D002867:Chromones; D019938:Cyclin D1; D048049:Extracellular Signal-Regulated MAP Kinases; D048031:JNK Mitogen-Activated Protein Kinases; D009025:Morpholines; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; D019253:Proto-Oncogene Proteins c-bcl-2; D013429:Sulfatases; D015238:Sulfotransferases; D051025:bcl-Associated Death Protein; C494819:BAD protein, human; C530104:CCND1 protein, human; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; C470792:SULF2 protein, human; C505407:CASP3 protein, human; C505520:CASP7 protein, human